Harbinger Capital
www.harbert.net/capital-partnersHarbinger Capital is a multi-billion dollar hedge fund founded in 2001 and is led by its Co-Founder and Chief Investment Officer, Philip Falcone, who has over 20 years of investment experience across an array of market cycles. The Harbinger Team is disciplined and value oriented, focusing on alpha generating ideas that are uncorrelated to investment cycles. The firm combines a flexible, innovative approach to uncovering opportunity with a thorough investment process. Each investment undergoes rigorous fundamental research, extensive vetting, and seeks an identifiable catalyst for value realization. Harbinger regards risk management as a critical component of the investment process and actively manages risk at three levels: portfolio, position and operations. The firm offers several strategies which emphasize different opportunities, each based on the same time-tested fundamental investment and risk management processes.
View Older Stories
-
HC2 Holdings CEO Phil Falcone Voluntarily Commits to Forgo Bonus Until HC2 Stock Price Reaches $7.50
-
Pansend Life Sciences' Portfolio Company, R2 Technologies, Receives Additional $10 Million Equity Investment From Huadong Medicine Company Limited
-
HC2 Holdings Sends Letter to Stockholders Correcting Gorzynski’s Smear Campaign Disguised as a Consent Solicitation
-
MG Capital Releases Presentation Detailing Nominees’ Plan and Strategy for a Better HC2
-
HC2 Holdings Sends Letter To Stockholders Highlighting The Strengths Of The Board Of Directors And Exposing The Shortcomings Of Percy Rockdale’s Woefully Unqualified And Inexperienced Slate Of Nomin
-
HC2 HOLDINGS FILES DEFINITIVE CONSENT REVOCATION STATEMENT AND SENDS LETTER TO STOCKHOLDERS
-
HC2 Holdings Announces Separation of Chairman and Chief Executive Officer Roles
-
HC2 Holdings Provides Business Update in Response to COVID-19 Impact
-
HC2 Broadcasting Helping McAllen, Texas Communicate Critical COVID-19 Updates over its Extensive Over-the-Air Network
-
HC2 Holdings Reports Fourth Quarter and Full Year 2019 Results
-
HC2 HOLDINGS ISSUES STATEMENT REGARDING PERCY ROCKDALE’S PRELIMINARY CONSENT SOLICITATION FILING
-
HC2 Holdings to Announce Fourth Quarter and Fiscal Year 2019 Financial Results
-
HC2 Holdings Completes Sale of Global Marine Group
-
HC2 Holdings Announces Appointment of Julie Springer, TransUnion Chief Marketing and Communications Officer, to its Board of Directors
-
HC2 Holdings (HCHC) in Advanced Discussions to Sell Continental Insurance, Retains Advisor to Explore Strategic Options on DBM Global
-
HC2 Holdings in Advanced Discussions to Sell Continental Insurance, Retains Advisor to Explore Strategic Options on DBM Global
-
HC2 Holdings (HCHC) to Sell Global Marine Group, Excluding the HMN Joint Venture, for $250 Million
-
HC2 Holdings Announces Definitive Agreement to Sell Global Marine Group, Excluding the HMN Joint Venture, for $250 Million
-
HC2 Holdings Reports Third Quarter 2019 Results
-
HC2's Marine Services Segment Announces Sale of Huawei Marine Networks Joint Venture
-
HC2 Broadcasting Completes $79 Million Financing
-
HC2 Holdings to Announce Third Quarter 2019 Financial Results
-
HC2 Holdings Reports Second Quarter 2019 Results
-
Pansend Life Sciences’ Portfolio Company MediBeacon Announces $30 Million Investment from Huadong Medicine and Exclusive Commercialization Partnership in Greater China
-
HC2 Holdings to Announce Second Quarter 2019 Financial Results
-
Pansend Life Sciences’ Portfolio Company, R2 Dermatology, Enters Into Exclusive China/Asia-Pacific Distribution Agreement
-
HC2 Holdings Reports First Quarter 2019 Results
-
HC2 Holdings to Announce First Quarter 2019 Financial Results
-
HC2 Holdings Reports Fourth Quarter and Full Year 2018 Results
-
HC2 Holdings to Announce Fourth Quarter and Fiscal Year 2018 Financial Results
-
HC2 Portfolio Company DBM Global Inc. Completes Acquisition of GrayWolf Industrial
-
HC2 Holdings Reports Third Quarter 2018 Results
-
HC2 Holdings Sets Third Quarter 2018 Earnings Release Date And Webcast
-
HC2 Holdings (HCHC) to Explore Strategic Alternatives for Global Marine Subsidiary
-
HC2 to Explore Strategic Alternatives for Global Marine Subsidiary
-
HC2 Portfolio Company MediBeacon™ Granted Breakthrough Device Status From FDA for Transdermal GFR Measurement System
-
FDA Grants Breakthrough Device Status for MediBeacon's Transdermal GFR Measurement System
-
HC2 Portfolio Company DBM Global Inc. To Acquire GrayWolf Industrial, A Leading Provider Of Specialty Maintenance, Repair And Installation Services
-
HC2 Broadcasting Launches Network Partnership With The Christian Broadcasting Network
-
Parent Company of HC2 Telecom Subsidiary PTGi-ICS Changes Name to ICS Group Holdings Inc.
-
HC2 Portfolio Company Continental General Insurance Completes Acquisition of $2.4 Billion Long-Term Care Insurance Business From Humana Inc.
-
HC2 Holdings Reports Second Quarter 2018 Results
-
HC2 Holdings Sets Second Quarter 2018 Earnings Release Date and Webcast
-
Communications Strategy and Policy Expert Rebecca Hanson Joins HC2 Broadcasting Subsidiary
-
HC2 Completes Sale of Pansend Life Sciences Portfolio Company BeneVir Biopharm to Janssen Biotech, Inc. for Up to $1.04 Billion
-
HC2 Holdings Reports First Quarter 2018 Results
-
HC2 Holdings (HCHC) Says Pansend Life Sciences Portfolio Company BeneVir Biopharm to be Acquired by Janssen Biotech (JNJ) for up to $1.04 Billion
-
HC2 Announces Pansend Life Sciences Portfolio Company BeneVir Biopharm to be Acquired by Janssen Biotech, Inc. for up to $1.04 Billion
-
HC2 Holdings Sets First Quarter 2018 Earnings Release Date and Webcast
-
HC2 Holdings Reports Fourth Quarter and Full Year 2017 Results

